Should Rituximab Be Considered for Relapsing Forms of MS? Some Specialists Make the Case for It

A new assessment of monoclonal antibody therapies approved to treat relapsing forms of multiple sclerosis (MS) found that they are clinically effective but priced too high to be considered cost-effective.